← Back to Search

1 for Peripheral Arterial Disease

Phase 2
Waitlist Available
Research Sponsored by AMAG Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects with symptoms of PAD
Scheduled for DSA
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 weeks
Awards & highlights

Study Summary

The purpose of this study is to compare the difference between two magnetic resonance imaging (MRI) techniques for visualizing arteries. The study hypothesizes that one method that relies upon imaging flowing blood in the pelvic and leg arteries will not be as accurate or efficient as injecting a safe imaging agent to change the appearance of the blood on the MRI. Both methods will be compared with Digital Subtraction Angiography (DSA).

Eligible Conditions
  • Peripheral Arterial Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To assess sensitivity and specificity of non-contrast MRA and VE-MRI at three ferumoxytol dosing levels
Secondary outcome measures
To assess positive and negative predictive values of VE-MRI using ferumoxytol at different dosing levels.

Trial Design

3Treatment groups
Experimental Treatment
Group I: 3Experimental Treatment1 Intervention
Dose 3 versus non-contrast MRA
Group II: 2Experimental Treatment1 Intervention
Dose 2 versus non-contrast MRA
Group III: 1Experimental Treatment1 Intervention
Dose 1 versus non-contrast MRA
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ferumoxytol
FDA approved

Find a Location

Who is running the clinical trial?

AMAG Pharmaceuticals, Inc.Lead Sponsor
43 Previous Clinical Trials
11,258 Total Patients Enrolled
William Strauss, MDStudy DirectorAMAG Pharmaceuticals, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)
2008. "Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00707876.
All > Pad
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top